Monte Rosa Therapeutics, Inc. Operating Expenses
Monte Rosa Therapeutics, Inc. (GLUE) reported Operating Expenses of $58.10 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-06
- Monte Rosa Therapeutics, Inc. operating expenses for the quarter ending 2026-06-30 was $58.10M, a 49.94% increase year-over-year.
- Monte Rosa Therapeutics, Inc. operating expenses for the quarter ending 2026-03-31 was $54.24M, a 32.65% increase year-over-year.
- Monte Rosa Therapeutics, Inc. operating expenses for the quarter ending 2025-12-31 was $52.50M, a 10.19% increase year-over-year.
- Monte Rosa Therapeutics, Inc. operating expenses for the quarter ending 2025-09-30 was $45.74M, a 27.98% increase year-over-year.
- Monte Rosa Therapeutics, Inc. operating expenses for fiscal 2025 was $177.88M, a 13.49% increase from fiscal 2024.
- Monte Rosa Therapeutics, Inc. operating expenses for fiscal 2024 was $156.73M, a 9.37% increase from fiscal 2023.
- Monte Rosa Therapeutics, Inc. operating expenses for fiscal 2023 was $143.31M, a 27.52% increase from fiscal 2022.
- Monte Rosa Therapeutics, Inc. operating expenses for fiscal 2022 was $112.38M, a 54.20% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $58.10M 10-Q · filed 2026-08-06 | $112.34M 10-Q · filed 2026-08-06 | $164.84M derived: sum of 3 quarters · filed 2026-08-06 | $210.58M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $54.24M 10-Q · filed 2026-05-07 | $106.74M derived: sum of 2 quarters · filed 2026-05-07 | $152.48M derived: sum of 3 quarters · filed 2026-05-07 | $191.23M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $52.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $98.24M derived: sum of 2 quarters · filed 2026-03-17 | $136.99M derived: sum of 3 quarters · filed 2026-08-06 | $177.88M 10-K · filed 2026-03-17 |
| 2025-09-30 | $45.74M 10-Q · filed 2025-11-06 | $84.49M derived: sum of 2 quarters · filed 2026-08-06 | $125.38M 10-Q · filed 2025-11-06 | $173.03M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $38.75M 10-Q · filed 2026-08-06 | $79.64M 10-Q · filed 2026-08-06 | $127.28M derived: sum of 3 quarters · filed 2026-08-06 | $163.03M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $40.89M 10-Q · filed 2026-05-07 | $88.54M derived: sum of 2 quarters · filed 2026-05-07 | $124.28M derived: sum of 3 quarters · filed 2026-05-07 | $161.62M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $47.64M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $83.39M derived: sum of 2 quarters · filed 2026-03-17 | $120.72M derived: sum of 3 quarters · filed 2026-03-17 | $156.73M 10-K · filed 2026-03-17 |
| 2024-09-30 | $35.74M 10-Q · filed 2025-11-06 | $73.08M derived: sum of 2 quarters · filed 2025-11-06 | $109.09M 10-Q · filed 2025-11-06 | $143.95M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $37.34M 10-Q · filed 2025-08-07 | $73.35M 10-Q · filed 2025-08-07 | $108.21M derived: sum of 3 quarters · filed 2025-08-07 | $145.18M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $36.01M 10-Q · filed 2025-05-08 | $70.87M derived: sum of 2 quarters · filed 2025-05-08 | $107.84M derived: sum of 3 quarters · filed 2025-05-08 | $145.06M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $34.86M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $71.83M derived: sum of 2 quarters · filed 2025-03-20 | $109.05M derived: sum of 3 quarters · filed 2025-03-20 | $143.31M 10-K · filed 2025-03-20 |
| 2023-09-30 | $36.97M 10-Q · filed 2024-11-07 | $74.19M derived: sum of 2 quarters · filed 2024-11-07 | $108.45M 10-Q · filed 2024-11-07 | $140.94M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $37.22M 10-Q · filed 2024-08-08 | $71.48M 10-Q · filed 2024-08-08 | $103.97M derived: sum of 3 quarters · filed 2024-08-08 | $132.33M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $34.26M 10-Q · filed 2024-05-09 | $66.75M derived: sum of 2 quarters · filed 2024-05-09 | $95.11M derived: sum of 3 quarters · filed 2024-05-09 | $122.34M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $32.49M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $60.85M derived: sum of 2 quarters · filed 2024-03-14 | $88.08M derived: sum of 3 quarters · filed 2024-03-14 | $112.38M 10-K · filed 2024-03-14 |
| 2022-09-30 | $28.36M 10-Q · filed 2023-11-09 | $55.59M derived: sum of 2 quarters · filed 2023-11-09 | $79.89M 10-Q · filed 2023-11-09 | $103.28M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $27.23M 10-Q · filed 2023-08-10 | $51.53M 10-Q · filed 2023-08-10 | $74.92M derived: sum of 3 quarters · filed 2023-08-10 | $94.79M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $24.30M 10-Q · filed 2023-05-11 | $47.69M derived: sum of 2 quarters · filed 2023-05-11 | $67.56M derived: sum of 3 quarters · filed 2023-05-11 | $85.68M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $23.39M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $43.26M derived: sum of 2 quarters · filed 2023-03-16 | $61.38M derived: sum of 3 quarters · filed 2023-03-16 | $72.88M 10-K · filed 2023-03-16 |
| 2021-09-30 | $19.87M 10-Q · filed 2022-11-10 | $37.99M derived: sum of 2 quarters · filed 2022-11-10 | $49.49M 10-Q · filed 2022-11-10 | $61.43M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $18.12M 10-Q · filed 2022-08-11 | $29.63M 10-Q · filed 2022-08-11 | $41.56M derived: sum of 3 quarters · filed 2022-08-11 | $47.95M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $11.50M 10-Q · filed 2022-05-11 | $23.44M derived: sum of 2 quarters · filed 2022-05-11 | $29.83M derived: sum of 3 quarters · filed 2022-05-11 | $35.22M derived: sum of 4 quarters · filed 2022-05-11 |
| 2020-12-31 | $11.94M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | $18.32M derived: sum of 2 quarters · filed 2022-03-29 | $23.72M derived: sum of 3 quarters · filed 2022-03-29 | $28.01M 10-K · filed 2022-03-29 |
| 2020-09-30 | $6.39M 10-Q · filed 2021-11-10 | $11.78M derived: sum of 2 quarters · filed 2021-11-10 | $16.07M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $5.40M 10-Q · filed 2021-08-12 | $9.69M 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |